GO:0046339 diacylglycerol metabolic process: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046339 diacylglycerol metabolic process describes all biochemical reactions and pathways involving diacylglycerol (DAG), a glyceride with two acyl chains and a third variable group.
• DAG is a central lipid second messenger produced by phospholipase C and phospholipase D, and it activates protein kinase C (PKC) isoforms and other targets.
• DAG metabolic flux is tightly linked to phosphatidic acid (PA) and phosphatidylinositol cycles, influencing neurotransmission and membrane dynamics.
• Hepatic DAG accumulation is a key mediator of lipid-induced insulin resistance through PKCε activation and impaired insulin receptor signaling.
• Dietary 1,3-diacylglycerol can modulate urate transporters and inflammasomes, showing systemic metabolic effects of DAG species.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of DAG metabolic enzymes in metabolic disease and cancer research.
Description
Diacylglycerol (DAG) is a neutral lipid that functions both as an intermediate in glycerolipid biosynthesis and as a potent lipid second messenger. The Gene Ontology term GO:0046339, diacylglycerol metabolic process, encompasses the chemical reactions and pathways involving DAG, including its synthesis, interconversion, and degradation. DAG is generated primarily through the hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C and from phosphatidic acid by phosphatidic acid phosphatase, and it is also produced by phospholipase D-mediated phosphatidylcholine hydrolysis. These pathways place DAG at the intersection of lipid metabolism and signal transduction, making it a critical node for cellular regulation. DAG exerts many of its signaling functions by recruiting and activating protein kinase C (PKC) isoforms and other C1-domain-containing proteins to membranes. In addition, DAG is a substrate for diacylglycerol kinases, which convert it to phosphatidic acid, and for diacylglycerol lipases, which release arachidonic acid for eicosanoid production. The balance between DAG synthesis and consumption determines the duration and amplitude of DAG signals, which in turn influence processes such as neurotransmission, insulin sensitivity, and immune cell activation. Dysregulated DAG metabolism is implicated in hepatic insulin resistance, type 2 diabetes, and hyperuricemia, among other conditions. For researchers, GO:0046339 provides a structured framework to study how specific enzymes and regulatory inputs shape DAG pools and downstream physiology. This article reviews the definition, mechanisms, key genes, disease links, and experimental strategies for investigating diacylglycerol metabolic process.
diacylglycerol metabolic process At A Glance
| GO ID | GO:0046339 |
|---|---|
| GO term | diacylglycerol metabolic process |
| Ontology | biological_process |
| Synonym | diacylglycerol metabolism; diglyceride metabolism |
| Definition | The chemical reactions and pathways involving diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group. |
| Major function | Production, interconversion, and degradation of diacylglycerol as a lipid second messenger and biosynthetic intermediate. |
| Key enzymes | Phospholipase C, phospholipase D, phosphatidic acid phosphatase, diacylglycerol kinase, diacylglycerol lipase. |
| Cellular context | Membrane-associated, especially plasma membrane and endoplasmic reticulum. |
| Related pathways | Phosphatidylinositol signaling, phosphatidic acid metabolism, glycerolipid biosynthesis, PKC signaling. |
What Is GO:0046339?
GO:0046339 diacylglycerol metabolic process is defined as the chemical reactions and pathways involving diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group. In practice, this term covers the enzymatic synthesis of DAG from phosphatidic acid or phosphatidylinositol precursors, its phosphorylation to phosphatidic acid, its hydrolysis to monoacylglycerol and free fatty acids, and its interconversion with other glycerolipids. The term is a biological process and includes both biosynthetic and catabolic routes that determine cellular DAG levels and signaling output.
Why Is diacylglycerol metabolic process Important in Cell Biology?
Diacylglycerol metabolic process is important because DAG is both a central intermediate in glycerolipid synthesis and a lipid second messenger that controls protein kinase C and other signaling proteins. The balance of DAG production and clearance regulates membrane trafficking, neurotransmission, and metabolic homeostasis, and its dysregulation contributes to insulin resistance, type 2 diabetes, and other metabolic disorders. Understanding GO:0046339 therefore helps researchers connect lipid enzyme activity to cellular signaling and disease phenotypes.
• DAG is a key lipid second messenger that activates PKC isoforms and other C1-domain proteins.
• DAG is an essential intermediate in the synthesis of phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol.
• Hepatic DAG accumulation is linked to PKCε activation and impaired insulin receptor signaling in insulin resistance.
• DAG produced by phospholipase D participates in immune and inflammatory signaling.
• DAG kinases convert DAG to phosphatidic acid, terminating DAG signals and generating another signaling lipid.
• DAG lipases release arachidonic acid, linking DAG metabolism to eicosanoid production.
• Dietary 1,3-DAG can modulate urate transporters and inflammasomes, affecting systemic metabolism.
• Exercise training alters muscle insulin sensitivity, which may involve changes in DAG metabolism.
• DAG metabolic enzymes are candidate drug targets for metabolic and inflammatory diseases.
• CRISPR screens can identify genes that regulate DAG levels and downstream signaling.
What Happens During diacylglycerol metabolic process?
Synthesis of DAG from phosphatidylinositol 4,5-bisphosphate
In simple terms: DAG is made when an enzyme cuts a membrane lipid called PIP2 into two pieces.
Phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate to produce inositol 1,4,5-trisphosphate and DAG, a reaction that is a major source of signaling DAG at the plasma membrane. This pathway links G-protein-coupled receptor and receptor tyrosine kinase signaling to DAG-dependent effectors such as PKC.
Synthesis of DAG from phosphatidic acid
In simple terms: DAG can also be made by removing a phosphate group from another lipid called phosphatidic acid.
Phosphatidic acid phosphatase (PAP) enzymes dephosphorylate phosphatidic acid to generate DAG, which is a key step in glycerolipid biosynthesis and also contributes to signaling DAG pools. This route connects DAG metabolism to phosphatidic acid produced by phospholipase D and diacylglycerol kinase.
Phosphorylation of DAG to phosphatidic acid
In simple terms: DAG can be converted back to phosphatidic acid by adding a phosphate group.
Diacylglycerol kinases phosphorylate DAG to form phosphatidic acid, thereby terminating DAG signals and generating a lipid that can regulate membrane curvature and recruit specific effector proteins. This reaction is a major mechanism for attenuating DAG-mediated PKC activation.
Hydrolysis of DAG by diacylglycerol lipases
In simple terms: DAG can be broken down to release free fatty acids, including arachidonic acid.
Diacylglycerol lipases hydrolyze DAG to monoacylglycerol and free fatty acids, including arachidonic acid, which serves as a precursor for eicosanoids. This catabolic route contributes to the termination of DAG signaling and to the production of lipid mediators of inflammation.
DAG in glycerolipid biosynthesis
In simple terms: DAG is a building block for making other lipids like phosphatidylcholine and triacylglycerol.
DAG serves as a substrate for choline phosphotransferase and ethanolamine phosphotransferase in the synthesis of phosphatidylcholine and phosphatidylethanolamine, and for diacylglycerol acyltransferases in triacylglycerol synthesis. These biosynthetic reactions integrate DAG metabolism with membrane lipid homeostasis and energy storage.
Key Genes Involved in GO:0046339 diacylglycerol metabolic process
The following genes encode enzymes and regulators that directly participate in or control diacylglycerol metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLCB1 | Phospholipase C beta 1; hydrolyzes PIP2 to produce DAG and IP3 | G-protein-coupled receptor signaling; neuronal DAG production |
| PLCG1 | Phospholipase C gamma 1; produces DAG downstream of receptor tyrosine kinases | Cancer signaling; DAG-mediated PKC activation |
| PLD1 | Phospholipase D 1; produces phosphatidic acid, which can be converted to DAG | Immune signaling; DAG generation via PA phosphatase |
| PLD2 | Phospholipase D 2; generates phosphatidic acid for DAG production | Membrane trafficking; signaling |
| DGKA | Diacylglycerol kinase alpha; phosphorylates DAG to phosphatidic acid | Termination of DAG signaling; T-cell activation |
| DGKZ | Diacylglycerol kinase zeta; regulates DAG levels | Immune and neuronal signaling |
| DGKH | Diacylglycerol kinase eta; converts DAG to phosphatidic acid | Bipolar disorder and signaling research |
| DAGLA | Diacylglycerol lipase alpha; hydrolyzes DAG to 2-arachidonoylglycerol | Endocannabinoid synthesis; neurotransmission |
| DAGLB | Diacylglycerol lipase beta; hydrolyzes DAG | Endocannabinoid system; lipid signaling |
| LPIN1 | Lipin 1; phosphatidic acid phosphatase; converts PA to DAG | Lipid metabolism; insulin sensitivity |
| LPIN2 | Lipin 2; phosphatidic acid phosphatase | Glycerolipid synthesis; metabolic disease |
| LPIN3 | Lipin 3; phosphatidic acid phosphatase | DAG production; lipid homeostasis |
| PRKCE | Protein kinase C epsilon; activated by DAG | Insulin resistance; hepatic lipid signaling |
| PRKCA | Protein kinase C alpha; DAG-activated | Cell proliferation; cancer |
| PRKCD | Protein kinase C delta; DAG-activated | Apoptosis; immune signaling |
| DGAT1 | Diacylglycerol acyltransferase 1; converts DAG to triacylglycerol | Lipid storage; obesity research |
| DGAT2 | Diacylglycerol acyltransferase 2; converts DAG to triacylglycerol | Hepatic steatosis; insulin resistance |
| CDS1 | CDP-diacylglycerol synthase 1; uses PA to make CDP-DAG | Phospholipid synthesis; DAG metabolism |
How Is diacylglycerol metabolic process Regulated?
Diacylglycerol metabolic process is regulated at multiple levels. Hormones and neurotransmitters activate phospholipase C through G-protein-coupled receptors, increasing DAG production. Insulin signaling can modulate DAG levels through effects on phosphatidic acid phosphatase and diacylglycerol kinase activities. Calcium and Rap1 signaling intersect with DAG pathways to control PKC activation and downstream responses. Exercise training alters muscle insulin sensitivity, which may involve changes in DAG metabolism. Additionally, dietary factors such as 1,3-diacylglycerol can influence systemic DAG-related pathways.
diacylglycerol metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKCE | Hepatic insulin resistance, type 2 diabetes | Liver-specific knockout or point-mutation knock-in in mice |
| LPIN1 | Lipid metabolism disorders, insulin resistance | Knockout and overexpression cell models |
| DGAT2 | Hepatic steatosis, insulin resistance | Liver-specific knockout and knock-in models |
| DAGLA | Neurotransmission, endocannabinoid signaling | Neuronal knockout and point-mutation models |
| PLCG1 | Cancer cell proliferation | Cancer cell line knockout and overexpression |
Hepatic insulin resistance and type 2 diabetes
Accumulation of hepatic DAG activates PKCε, which impairs insulin receptor signaling and contributes to insulin resistance and type 2 diabetes. Inhibiting ceramide synthesis can prevent lipid-induced insulin resistance through the DAG-PKCε pathway, highlighting DAG as a therapeutic target.
Hyperuricemia and inflammasome regulation
Dietary 1,3-diacylglycerol ameliorates hyperuricemia in mice by dual modulation of urate transporters and inflammasomes, demonstrating that DAG species can affect systemic metabolic and inflammatory pathways.
Neurotransmission and neurological disorders
Phosphatidic acid and DAG metabolism are important for neurotransmission, and disruptions in these pathways may contribute to neurological conditions. DAG lipases produce endocannabinoids that modulate synaptic activity.
Cancer signaling
DAG-activated PKC isoforms and phospholipase C enzymes are frequently altered in cancer, where they promote proliferation and survival. Targeting DAG metabolic enzymes is an active area of cancer research.
From diacylglycerol metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DGKA alter DAG levels and PKC signaling? | DGKA knockout cell line (e.g., HEK293 or Jurkat) |
| Does a specific point mutation in PRKCE affect insulin receptor phosphorylation? | PRKCE point-mutation knock-in in hepatocytes |
| Can overexpression of LPIN1 increase DAG and triacylglycerol synthesis? | LPIN1 overexpression in HepG2 cells |
| Does tagged DGAT2 localize to lipid droplets? | DGAT2 knock-in with fluorescent tag in HeLa cells |
| Which genes regulate DAG levels under lipid overload? | CRISPR library screening in hepatocytes |
| Does DAGLA knockout affect endocannabinoid production? | DAGLA knockout in neuronal cells |
How to Study the diacylglycerol metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | DAG species and related lipids | Quantifying DAG changes in knockout or overexpression cells |
| CRISPR knockout screening | Genes affecting DAG levels | Identifying regulators of DAG metabolism |
| Western blot | PKC phosphorylation and insulin receptor signaling | Assessing DAG downstream effects |
| Fluorescence microscopy | DAG sensor localization | Live-cell DAG dynamics |
| qPCR | Expression of DAG-metabolizing enzymes | Validating knockout or overexpression |
| Enzyme activity assay | Diacylglycerol kinase or lipase activity | Functional characterization of mutants |
| Co-immunoprecipitation | Protein-protein interactions | Identifying DAG enzyme complexes |
| RNA-seq | Transcriptional changes | Global effects of DAG pathway perturbations |
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics quantifies DAG species and related lipids, enabling researchers to measure changes in DAG metabolic flux.
CRISPR knockout and knock-in screens
CRISPR knockout libraries can identify genes that regulate DAG levels and downstream signaling, while knock-in models allow precise mutation of DAG-metabolizing enzymes.
Phosphorylation and signaling assays
Western blotting for PKC substrates and insulin receptor phosphorylation assesses DAG-mediated signaling outcomes.
Fluorescent imaging of lipid sensors
Genetically encoded DAG sensors and fluorescent tags can visualize DAG dynamics in live cells.
How CRISPR Can Be Used to Study GO:0046339 diacylglycerol metabolic process
Knockout
CRISPR knockout of genes such as DGKA, DGAT2, or LPIN1 eliminates enzyme function, allowing researchers to determine their contribution to DAG levels and signaling. Knockout cell lines are valuable for lipidomics and signaling assays.
Point Mutation
Point-mutation knock-in can mimic disease-associated variants or disable catalytic residues in DAG-metabolizing enzymes, enabling precise structure-function studies.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous DAG enzyme loci allows visualization and purification of native complexes without overexpression artifacts.
Overexpression
Overexpression of DAG enzymes such as LPIN1 or DGAT2 can amplify DAG production or consumption, revealing dose-dependent effects on lipid homeostasis and insulin signaling.
How EDITGENE Supports diacylglycerol metabolic process Research
Researchers studying diacylglycerol metabolic process-related genes often need to determine whether a candidate gene is causally involved in DAG regulation, signaling, or disease phenotypes. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for diacylglycerol metabolic process research.
Frequently Asked Questions About diacylglycerol metabolic process
What is GO:0046339 diacylglycerol metabolic process?
GO:0046339 is a Gene Ontology biological process term describing the chemical reactions and pathways involving diacylglycerol, a glyceride with two acyl groups and a third variable group.
What genes are involved in diacylglycerol metabolic process?
Key genes include PLCB1, PLCG1, PLD1, PLD2, DGKA, DGKZ, DAGLA, DAGLB, LPIN1, LPIN2, LPIN3, PRKCE, DGAT1, and DGAT2.
How is diacylglycerol produced in cells?
DAG is produced by phospholipase C hydrolysis of PIP2, by phosphatidic acid phosphatase acting on phosphatidic acid, and by phospholipase D pathways.
What is the role of DAG in insulin resistance?
Hepatic DAG activates PKCε, which impairs insulin receptor signaling and contributes to insulin resistance and type 2 diabetes.
Which enzymes degrade diacylglycerol?
Diacylglycerol kinases phosphorylate DAG to phosphatidic acid, and diacylglycerol lipases hydrolyze DAG to monoacylglycerol and fatty acids.
How can I study diacylglycerol metabolic process in the lab?
Common methods include lipidomics, CRISPR knockout or knock-in models, Western blotting for PKC signaling, and fluorescent DAG sensors.
What diseases are linked to DAG metabolism?
DAG metabolism is linked to hepatic insulin resistance, type 2 diabetes, hyperuricemia, neurological disorders, and cancer.
Can CRISPR be used to study DAG metabolism?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of DAG-metabolizing enzymes for functional studies.
What is the difference between DAG and phosphatidic acid?
DAG lacks the phosphate group present in phosphatidic acid; interconversion between them is catalyzed by diacylglycerol kinases and phosphatidic acid phosphatases.
How does exercise affect DAG metabolism?
Exercise training improves muscle insulin sensitivity, which may involve changes in DAG metabolism and PKC signaling.
Conclusion
GO:0046339 diacylglycerol metabolic process is a fundamental biological process that integrates lipid biosynthesis with second messenger signaling. Its dysregulation is implicated in insulin resistance, type 2 diabetes, hyperuricemia, and cancer, making it a high-priority area for mechanistic and therapeutic research. Advances in CRISPR-based models and lipidomics now allow precise interrogation of DAG enzymes and pathways in relevant cell types. Researchers can leverage EDITGENE's knockout, knock-in, overexpression, and screening services to dissect the causal roles of DAG-metabolizing genes and accelerate discovery in metabolic disease and beyond.
References
- 1. Strålfors P. 1997. Insulin second messengers.. Bioessays 19(4):327-35 PMID: 9136630
- 2. Xu W et al.. 2024. Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptor(T1150) phosphorylation pathway.. Cell Rep 43(10):114746 PMID: 39302831
- 3. Perry RJ et al.. 2014. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.. Nature 510(7503):84-91 PMID: 24899308
- 4. Raben DM et al.. 2017. Phosphatidic acid and neurotransmission.. Adv Biol Regul 63:15-21 PMID: 27671966
- 5. Kosuru R et al.. 2020. Integration of Rap1 and Calcium Signaling.. Int J Mol Sci 21(5) PMID: 32120817
- 6. Pesta D et al.. 2025. Determinants of increased muscle insulin sensitivity of exercise-trained versus sedentary normal weight and overweight individuals.. Sci Adv 11(1):eadr8849 PMID: 39742483
- 7. Zhang Y et al.. 2025. Dietary 1,3-diacylglycerol ameliorates hyperuricemia via dual modulation of urate transporters and inflammasomes in mice.. Food Funct 16(18):7253-7265 PMID: 40843528
- 8. Billah MM. 1993. Phospholipase D and cell signaling.. Curr Opin Immunol 5(1):114-23 PMID: 8383981
